MIGH
Mangaluru, Karnataka, India

Mangaluru Institute for Global Health

Health economics and policy research for vaccines, health financing and disease burden, for governments, multilateral agencies and research partners.

Section 8 not-for-profit company Incorporated 29 June 2026 Founder & Director Dr Vittal Mogasale
About

Evidence for health decisions, from Mangaluru to the world

Advancing research and evidence in global health, health economics and health policy to improve population health, equity and the efficiency of health systems.

The Mangaluru Institute for Global Health (MIGH) is an independent, not-for-profit institute registered in India in 2026. It produces economic and policy evidence for decisions on vaccines, disease control and health financing.

MIGH works with governments, multilateral agencies, universities and research partners in India and internationally. Its work covers economic evaluation, costing and cost-of-illness studies, disease burden estimation, investment cases, priority setting, implementation research and training.

In its first phase MIGH provides technical and consultancy support. Over time it aims to grow into a full research institute with its own research programme. MIGH is led by its founder, Dr Vittal Mogasale.

Legal name
Mangaluru Institute for Global Health Foundation
Legal form
Section 8 not-for-profit company, limited by guarantee
Incorporated
29 June 2026, Registrar of Companies, Bangalore
Location
Mangaluru, Dakshina Kannada, Karnataka
CIN
U85499KA2026NPL223122
NGO Darpan ID
KA/2026/1143429
Section 8 licence
No. 187431
Research & projects

Areas of work

Economic evaluation and investment cases

Cost-effectiveness analysis, evaluation methodology and investment cases for vaccines, national programmes and global health agencies.

Burden of disease and cost of illness

Disease burden estimation and multi-country cost-of-illness studies to inform policy and investment planning.

Epidemiology and disease surveillance

Epidemiological analysis, disease burden modelling and costing of disease surveillance systems.

Infectious diseases and AMR

Research on typhoid, cholera and antimicrobial resistance in low- and middle-income countries.

Vaccine policy

Evidence for vaccine introduction and financing decisions, including typhoid conjugate and oral cholera vaccines.

Priority setting

Methods and tools for setting health priorities, including contributions to WHO-CHOICE and the WHO PRIORITI framework.

Health financing and UHC

Health financing analysis and costing of national health service packages to support universal health coverage.

Implementation research

Costing and evaluation of programme delivery, such as the public-sector introduction of typhoid conjugate vaccine in Navi Mumbai.

Training and capacity building

Costing tools, methods training and teaching for ministries of health, researchers and students.

Current projects

  • Economic evaluation of typhoid conjugate vaccine introduction strategies in India. Comparing the costs and health outcomes of alternative strategies for introducing typhoid conjugate vaccine, to inform national and state decisions.
Publications

Research output of the founding director

73peer-reviewed publications
35h-index (Google Scholar, Sep 2026)
~5,200citations (Google Scholar)
$40M+competitive grants secured

Key publications

  1. 2026
    Evaluating the impact and cost-effectiveness of typhoid conjugate vaccine schedules across diverse settings: a multi-model comparison
    Wenger CGC, Grantz KH, Menkir TF, … Mogasale V, et al. PLoS Med. 2026.
  2. 2026
    Burden of antimicrobial resistance in culture-confirmed Salmonella Typhi isolates in India from 1977 to 2024: a systematic review and meta-analysis
    Mogasale VV, Zhang P, John J, Farooqui HH, Ray A, Mogasale V, … Abbas K. PLoS Negl Trop Dis. 2026;20(4):e0014206. Senior author
  3. 2026
    Economic burden of typhoid fever by antimicrobial resistance in India: a modelling study 2023
    Mogasale VV, John J, Ray A, Farooqui HH, Mogasale V, Hutubessy R, … Abbas K. Lancet Reg Health Southeast Asia. 2026;47:100748. Senior author
  4. 2026
    Burden of typhoid fever and antimicrobial resistance in India (2023): a modelling study
    Mogasale VV, John J, Sahai N, Ray A, Farooqui HH, Mogasale V, et al. Lancet Reg Health Southeast Asia. 2026;44:100714. Senior author
  5. 2023
    Delivery cost of the first public sector introduction of typhoid conjugate vaccine in Navi Mumbai, India
    Song D, Pallas SW, Shimpi R, … Mogasale V. PLOS Glob Public Health. 2023;3(1):e0001396. Senior author
  6. 2023
    The potential global cost-effectiveness of prospective Strep A vaccines and associated implementation efforts
    Lee JS, Mogasale V, Kim S, et al. NPJ Vaccines. 2023;8(1):128. Senior author
  7. 2022
    WHO-led consensus statement on vaccine delivery costing: process, methods, and findings
    Levin A, Boonstoppel L, Brenzel L, … Mogasale V, et al. BMC Med. 2022;20(1):88.
  8. 2021
    Disruptions to childhood immunisation due to the COVID-19 pandemic
    Abbas K, Mogasale V. Lancet. 2021;398(10299):469-71.
  9. 2021
    Model-based estimation of the economic burden of cholera in Africa
    Mogasale V, Ngogoyo SM, Mogasale VV. BMJ Open. 2021;11(3):e044615. First author
  10. 2020
    Costing oral cholera vaccine delivery using a generic oral cholera vaccine delivery planning and costing tool (CholTool)
    Morgan W, Levin A, Hutubessy RC, Mogasale V. Hum Vaccin Immunother. 2020;16(12):3111-8. Senior author
  11. 2017
    A forecast of typhoid conjugate vaccine introduction and demand in typhoid endemic low- and middle-income countries to support vaccine introduction policy and decisions
    Mogasale V, Ramani E, Park IY, Lee JS. Hum Vaccin Immunother. 2017;13(9):2017-24. First author
  12. 2017
    A multi-country study of the economic burden of dengue fever: Vietnam, Thailand, and Colombia
    Lee JS, Mogasale V, Lim JK, Carabali M, et al. PLoS Negl Trop Dis. 2017;11(10):e0006037. Senior author
  13. 2016
    Oral cholera vaccination delivery cost in low- and middle-income countries: an analysis based on systematic review
    Mogasale V, Ramani E, Wee H, Kim JH. PLoS Negl Trop Dis. 2016;10(12):e0005124. First author
  14. 2014
    Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment
    Mogasale V, Maskery B, Ochiai RL, Lee JS, et al. Lancet Glob Health. 2014;2(10):e570-80. First author

Selected from 73 peer-reviewed publications, 2014 to 2026. Full list on Google Scholar

People

Leadership

Dr Vittal Mogasale

Dr Vittal Mogasale

Founder & Director

Public health physician (MBBS, MPH, PhD) and health economist with 25 years of experience in India, Australia, South Korea and Switzerland, and in projects across 22 countries in Africa and Asia. His work spans field epidemiology and surveillance, HIV and STI programmes, vaccine policy, economic evaluation and health financing.

Evidence behind global vaccine decisions

  • Led the typhoid conjugate vaccine investment case and demand forecast that informed Gavi's decision to finance its introduction.
  • Led the cost-effectiveness analysis of the WHO global cholera elimination plan.
  • Guided the WHO multi-model comparison of typhoid conjugate vaccine schedules, which generated economic evidence for global recommendations on a second dose.
  • Contributed economic and market-access analysis to the technology transfer and licensure of two oral cholera vaccines, Shanchol (India) and Euvichol (Korea).

WHO guidance and country tools

  • Contributed to 13 WHO and multi-agency guidance documents, including PRIORITI guidance on priority setting (2025), the G20 report on financing for pandemic preparedness (2025), the WHO position paper on RSV immunisation (2025) and the Quadripartite investment case on antimicrobial resistance (2024).
  • Co-developed costing tools used by programme managers: CholTool, a typhoid conjugate vaccine delivery costing tool and a cholera treatment costing tool.
  • Led WHO's collaboration with Nepal's Ministry of Public Health to cost national health service packages (2022–2025).

Field evidence in Asia and Africa

  • Led eight multi-country cost-of-illness studies and six field vaccination costing projects covering typhoid, cholera, HPV and measles-rubella vaccines.
  • Supported cholera vaccine introduction in India, Nepal, Ethiopia, Malawi and Mozambique, and the first public-sector typhoid conjugate vaccine introduction in India.
  • Earlier field work in India: polio surveillance across four districts of Bihar and STI services in 395 clinics across six states.

Institution building and funding

  • Founded the Policy and Economic Research Department at IVI and grew it from 2 to 12 staff, with more than 20 projects in 22 low- and middle-income countries.
  • Secured more than USD 40 million in competitive grants as principal investigator, co-applicant or co-investigator, including as principal investigator of RADAAR, a 22-country AMR consortium funded by the UK Fleming Fund.
  • Partnerships with more than 70 institutions; supervised doctoral and master's students.

Advisory roles with WHO and Gavi

  • Gavi Independent Review Committee, member (2020–2022)
  • Gavi Vaccine Investment Strategy for cholera, external expert (2013, 2018)
  • Gavi Strategic Demand Scenarios Expert Group, oral cholera vaccines (2021)
  • WHO Immunization and Vaccines-related Implementation Research Advisory Committee (IVIR-AC), participant (2014–2019)
  • WHO External Expert Group, cholera vaccine investment case (2018–2019)
  • WHO Working Group on typhoid conjugate vaccine model comparison (2022–2024)
  • WHO Working Group on delivery cost standardisation (2019–2021)
  • WHO Working Group on total system effectiveness modelling (2018–2020)
  • WHO Working Group on surveillance costing (2018)
  • Global Task Force on Cholera Control, participant (2016, 2018, 2019)

Current roles

  • Founder & Director, MIGH, Mangaluru (2026–present)
  • Member, UNICEF Expert Roster, Health Economics and Financing (2026–2029)
  • Scientific Reviewer, WHO Science Division (roster, 2026–present)
  • Adjunct Professor, Yonsei University, Seoul (2018–present)

Career

  • Health Economist, WHO headquarters, Geneva (2021–2025)
  • Founding Head, Policy and Economic Research, International Vaccine Institute, Seoul (2011–2021)
  • PhD scholar and Research Officer, University of Queensland, Brisbane (2007–2010)
  • Senior Technical Officer, FHI360, Avahan India AIDS Initiative, Mumbai (2004–2007)
  • Technical Officer, India-Canada HIV-AIDS Project, Jaipur (2004)
  • Surveillance Medical Officer, National Polio Surveillance Project, WHO India, Bihar (2000–2002)
  • Medical Officer, Truckers Community Health Project, Mangaluru (1998–2000)

Education: PhD, University of Queensland · MPH, Hebrew University of Jerusalem · MBBS, Manipal University

Contact

Get in touch

Emailvmogasale@gmail.com
AddressLight House Hill Road, Hampankatta
Mangaluru 575001, Karnataka, India